MetaCap

Ligand Pharmaceuticals Incorporated (LGND)

NASDAQ: LGNDHealth CareBiotechnology: Pharmaceutical PreparationsUSD

286.85-0.09 (-0.03%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

LGND stock chart

Technical analysis

Key statistics

All statistics
P/E (TTM)
115.20
Ex-dividend date
Apr 3, 2007
52-week range
175.89 – 326.63
Day range
283.01 – 291.33
Volume / Avg
259.77K / 230.79K
Beta
—

52-week range

$175.89$326.63

LGND stock today

On Nov 20, LGND ended the session at $286.85, shedding $0.09 (0.03%), versus the S&P 500's 3.70% decline. Shares are 12.2% below their 52-week high of $326.63, set on Jul 8, 2026 and 63.1% above the 52-week low of $175.89, in the middle of the past year's range. LGND is up 51.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 44.0%.

Ligand Pharmaceuticals trades at 115.2x its trailing twelve-month earnings per share of $2.49. Its forward P/E of 24.0x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Ligand Pharmaceuticals

Company profile

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Todd C. Davis Ph.D.
Headquarters
Jupiter, FL
Employees
47
Website
ligand.com

Financial highlights

Full financials

In fiscal 2025, Ligand Pharmaceuticals generated $268.1 million in revenue, up 60.4% from fiscal 2024, its 2nd consecutive year of revenue growth. Net income was $124.5 million, for a net margin of 46.4% versus a median of -1.8% in the prior 5 years. Operating margin was 15.3%.

Ligand Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$268.09M$167.13M$131.31M$196.25M$241.54M
Growth+60.40%+27.28%-33.09%-18.75%+47.68%
Net income$124.45M$-4.03M$52.15M$-33.36M$57.14M
EPS (diluted)$6.13$-0.22$2.94$-1.98$3.31

Analyst forecast

Forecast

Consensus (11 analysts)

strong_buy

Avg. price target

$361.27+25.94%

  • Strong buy 3
  • Buy 8
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $335.00High $406.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 29, 2026
EPS actual vs est.
$5.68 vs $1.42
Surprise
+300.00%

Dividends

Dividend history
Annual dividend
$0.00
Last payment
$9.36
Ex-dividend date
Apr 3, 2007

LGND news

All LGND news

Ligand Pharmaceuticals peers

Health Care sector
LGND peer companies
CompanyPrice% ChgMarket capCompare
ARWRArrowhead Pharmaceuticals Inc.41.37-5.22%$5.85Bvs LGND
GRFSGrifols S.A. ADR8.15-0.61%$5.55Bvs LGND
SUPNSupernus Inc.28.61+0.92%$5.94Bvs LGND
MIRMMirum Pharmaceuticals Inc.96.13+0.65%$6.28Bvs LGND
BLTEBelite Bio Inc ADR127.38-15.65%$5.17Bvs LGND
ABVXAbivax SA ADR73.20-9.24%$6.41Bvs LGND
MANEVeradermics Incorporated119.52-3.92%$5.04Bvs LGND
LQDALiquidia Corporation54.43-3.88%$4.90Bvs LGND

Indexes, lists and sector

Ligand Pharmaceuticals stock FAQ

What is Ligand Pharmaceuticals's stock price today?

LGND last traded at $286.85 as of Nov 20, 4:00 PM EST, down 0.03% on the day. Prices are delayed at least 15 minutes.

Does Ligand Pharmaceuticals pay a dividend?

Yes. Ligand Pharmaceuticals pays $0.00 per share annually. The most recent dividend of $9.36 had an ex-dividend date of Apr 3, 2007.

What is LGND's P/E ratio?

LGND trades at a trailing P/E ratio of 115.20 and a forward P/E of 24.00.

Who is Ligand Pharmaceuticals's CEO?

Mr. Todd C. Davis Ph.D. is the chief executive officer of Ligand Pharmaceuticals Incorporated, which has about 47 employees.

Has LGND ever split its stock?

Yes. The most recent LGND stock split was a 1603-for-1000 split on Nov 2, 2022, one of 2 splits on record.

What is the LGND 52-week high?

The 52-week high for LGND is $326.63 and the 52-week low is $175.89. The stock is currently 12.2% below its high.

Compare LGND